drugset / Trial / NCT02939183
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
Timeline
- Start
- 2017-01-17
- Primary completion
- 2022-10-06
- Completion
- 2022-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oprozomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Pomalidomide | Other / unclassified | — | — |